Despite this recent progress in understanding the link between abnormal PTMs and the aggregation of tau in AD, additional studies are required to understand how such abnormal PTMs are reflected in predominantly C-terminally truncated tau.8,46 Current findings nevertheless highlight the importance of mapping PTMs in order to better understand the pathophysiology of AD; moreover, increased insight into the role of PTMs will facilitate the identification of novel therapeutic targets and improve AD diagnostics. The gene discussed is MAPT; the disease is Alzheimer disease.